drugset / Trial / NCT02888730

Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients

NCT02888730

RandomizedParallel-groupTriple-blindTreatment

Summary

Patients with cystic fibrosis frequently develop chronic rhinosinusitis. Bacterial colonization is facilitated by a reduced mucociliary function and some previous studies suggest that the microbiology of the upper airways might influence the microbiology of the lower airway. The aim of this randomized control study is to demonstrate efficacy of antibiotic delivered by nebulized sonic aerosol therapy to decrease the bacterial load in sinuses and medium ostia and to improve the sino-nasal symptoms and endoscopic scores, quality of life and lung function

Timeline

Start
2017-02-16
Primary completion
2017-05-16
Completion
2019-07-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule 300 mg Inhaled